Andrea T. Cruz, MD, of the section of emergency medicine and infectious disease at Baylor College of Medicine, discusses findings from a study of the safety and completion of a 4-month course of rifampin for latent tuberculosis infection in children.
Cruz and colleague Jeffrey R. Starke, MD, an Infectious Diseases in Children editorial board member, found that the 4-month course of rifampin was well tolerated and effective.
Compared with a 9-month course of isoniazid, rifampin surpassed it for completion rate for all methods of delivery and was not statistically different for completion rates of self-administered therapy.
